The International Consortium for Health Outcomes Measurement (ICHOM), a health care transformation independent non-profit organisation, reported on Monday the addition of Neil Bacon as its new president and CEO.
Effective immediately, Dr Bacon succeeds ICHOM's outgoing Dr Christina Akerman, who has returned to her native Sweden after four highly successful years.
In the senior position, Dr Bacon, a nephrologist, will enhance quality measurement and change health care by developing, supporting and implementing the global outcome standards across the disease burden to the next level, as well as establish the first health care platform for benchmarking outcomes across countries.
Previously, Dr Bacon founded Doctors.net.uk in 1996, the world's largest online medical networks used by physicians to rapidly obtain clinical information, education, medical news and career opportunities, as well as founder and CEO of iWantGreatCare, an independent organisation enabling patients to rate and review their doctors, dentists, hospitals, after-care facilities and medications, in 2008.
ICHOM aim to transform health care worldwide through creating international standards for the outcomes that matter most for patients by using medical conditions. The organisation's standard sets have been developed in 26 conditions including stroke, diabetes, and ischemic heart disease, representing 25% of the global disease burden. ICHOM also helps providers to implement outcome measures and utilise outcomes to improve patient care.
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial
Clywedog Therapeutics activates all clinical centres and patient dosing in balomenib Phase 1b study
Qlife's Egoo Health platform selected for major AI-driven diabetes and MASLD project in China
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies